Fluorescence tagging and inducible depletion of PD-L2-expressing B-1 B cells in vivo

Annals of the New York Academy of Sciences

Volumn 1362, Issue 1, 2015, Pages 77-85

  Lee, Rebecca A ^a   Mao, Changchuin ^a   Vo, Hung ^a   Gao, Wenda ^b   Zhong, Xuemei ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Antagen Institute for Biomedical Research   (United States)

Author keywords

Diphtheria toxin receptor; L2pB1 cells; Monoallelic expression; TdTomato; ZsGreen

Indexed keywords

DIPHTHERIA TOXIN; IMMUNOGLOBULIN; INTERLEUKIN 10; PROGRAMMED DEATH 1 LIGAND 2; PDCD1LG2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; FLUORESCENCE; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; IN VIVO STUDY; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PERITONEAL CAVITY; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL COUNT; FLUORESCENCE IMAGING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; B-LYMPHOCYTE SUBSETS; CELL COUNT; GENE EXPRESSION REGULATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OPTICAL IMAGING; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN;

EID: 84959524968     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12865     Document Type: Article

References (37)

1. Latchman, Y. et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2: 261-268.
2. Zhong, X. et al. 2007. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur. J. Immunol. 37: 2405-2410.
3. Zhong, X. et al. 2009. A novel subpopulation of B-1 cells is enriched with autoreactivity in normal and lupus-prone mice. Arthritis Rheum. 60: 3734-3743.
4. Klinker, M.W. & S.K. Lundy. 2012. Multiple mechanisms of immune suppression by B lymphocytes. Mol. Med. 18: 123-137.
5. Zhang, Y. et al. 2006. Regulation of T cell activation and tolerance by PDL2. Proc. Natl. Acad. Sci. U.S.A. 103: 11695-11700.
6. Salama, A.D. et al. 2003. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198: 71-78.
7. Zhu, B. et al. 2006. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J. Immunol. 176: 3480-3489.
8. Pfistershammer, K. et al. 2006. No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur. J. Immunol. 36: 1104-1113.
9. Kaku, H. & T.L. Rothstein. 2010. Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter. Genes Immun. 11: 55-66.
10. Szymczak, A.L. et al. 2004. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat. Biotechnol. 22: 589-594.
11. Yen, H.H. & J.P. Scheerlinck. 2013. Biological activity of ovine IL-23 expressed using a foot-and-mouth disease virus 2A self-cleaving peptide. Cytokine 61: 744-746.
12. Hollander, G.A. et al. 1998. Monoallelic expression of the interleukin-2 locus. Science 279: 2118-2121.
13. + T cell clones. J. Immunol. 171: 2349-2353.
14. Mostoslavsky, R., F.W. Alt & K. Rajewsky. 2004. The lingering enigma of the allelic exclusion mechanism. Cell 118: 539-544.
15. Bouabe, H. 2012. Cytokine reporter mice: the special case of IL-10. Scand. J. Immunol. 75: 553-567.
16. Vance, R.E. et al. 2002. Implications of CD94 deficiency and monoallelic NKG2A expression for natural killer cell development and repertoire formation. Proc. Natl. Acad. Sci. U.S.A. 99: 868-873.
17. Saito, M. et al. 2001. Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat. Biotechnol. 19: 746-750.
18. Buch, T. et al. 2005. A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat. Methods 2: 419-426.
19. Mitamura, T. et al. 1995. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J. Biol. Chem. 270: 1015-1019.
20. Demircik, F., T. Buch & A. Waisman. 2013. Efficient B cell depletion via diphtheria toxin in CD19-Cre/iDTR mice. PLoS One 8: e60643.
21. Ehrenstein, M.R. & C.A. Notley. 2010. The importance of natural IgM: scavenger, protector and regulator. Nat. Rev. Immunol. 10: 778-786.
22. Gronwall, C., J. Vas & G.J. Silverman. 2012. Protective roles of natural IgM antibodies. Front. Immunol. 3: 66.
23. Carmack, C.E. et al. 1990. Rearrangement and selection of VH11 in the Ly-1 B cell lineage. J. Exp. Med. 172: 371-374.
24. +) B cells that recognize phosphatidyl choline. J. Exp. Med. 169: 1869-1877.
25. + (CD5) B cells that recognize phosphatidyl choline. Relationship to cells that secrete hemolytic antibody specific for autologous erythrocytes. J. Exp. Med. 168: 687-698.
26. Shaw, P.X. et al. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105: 1731-1740.
27. Shaw, P.X. et al. 2003. The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cells. J. Immunol. 170: 6151-6157.
28. Boes, M. et al. 1998. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J. Exp. Med. 188: 2381-2386.
29. Baumgarth, N. et al. 2000. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J. Exp. Med. 192: 271-280.
30. Cabiedes, J. et al. 2002. Characterization of anti-phosphatidylcholine polyreactive natural autoantibodies from normal human subjects. J. Autoimmun. 18: 181-190.
31. Vieira, P. & K. Rajewsky. 1988. The half-lives of serum immunoglobulins in adult mice. Eur. J. Immunol. 18: 313-316.
32. Brekke, O.H. & I. Sandlie. 2003. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2: 52-62.
33. Matsushita, T. et al. 2008. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118: 3420-3430.
34. Bouaziz, J.D., K. Yanaba & T.F. Tedder. 2008. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 224: 201-214.
35. Paciorkowski, N., L.D. Shultz & T.V. Rajan. 2003. Primed peritoneal B lymphocytes are sufficient to transfer protection against Brugia pahangi infection in mice. Infect. Immun. 71: 1370-1378.
36. Lampropoulou, V. et al. 2008. TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol. 180: 4763-4773.
37. O'Garra, A. et al. 1992. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur. J. Immunol. 22: 711-717.